Give Hospira a Shot

The struggling maker of generic injectable drugs may have a cure for ailing investors.

The last few years have been difficult for Hospira, the largest maker of generic injectable drugs. In 2010, Hospira (ticker: HSP) received a letter from the Food and Drug Administration, citing violation of quality standards at two of its manufacturing plants. Ever since, the company has been hard at work at resolving the issues.

The bulk of the remediation efforts have focused on its largest plant in Rocky Mount, N.C., which accounts for 25% of revenue. The company initially said that bringing its operations up to...